A New Drug in the Treatment of Advanced Skin Cancer (Melanoma); Nivolumab

According to the results of a study published recently by the Journal of Medical Oncology, nivolumab provides a long-term response in patients with advanced skin cancer (melanoma).
Skin cancer (melanoma) develops from cells called melanocytes, which give the skin its color. Cancer can develop on moles that appear later in life, in addition to moles that are congenitally present anywhere on the body. Excessive sun exposure during childhood is considered the primary cause of cancer developing on a mole.
The results of a study conducted on melanoma, which has a high risk of mortality compared with other types of skin cancer because it spreads to different parts of the body in its advanced stage, were published recently in the Journal of Medical Oncology. According to the results of this study, the investigational drug nivolumab, which is anti-PD-1, produced a long-term response in patients with advanced skin cancer (melanoma).
PD-1 is a protein that inhibits certain immune responses. By inhibiting the protein called PD-1, this drug may increase the immune system’s ability to fight cancer. Nivolumab is designed to block the PD-1 protein.
A total of 2008-2012 patients with advanced skin cancer (melanoma) between the years 107 participated in the study conducted to examine the efficacy of this drug. These outpatients received intravenous nivolumab once every 8 weeks in 2-week cycles. Overall survival, the drug’s long-term safety, and the duration of response after treatment ended were observed during and after the 96-week treatment period.
At the end of the study, the mean overall survival in patients with advanced melanoma was observed to be 16.8 months, while the 1-year survival rate was recorded as %62 and the 2-year survival rate as %43. The objective response rate to treatment was %31. Among 33 patients, the mean duration of response to treatment was determined to be 2 years. 17 of the patients did not continue treatment for health reasons other than disease progression. In 12 of these patients, a response continued to be observed 16 weeks and thereafter after treatment was discontinued. How long the participating patients can tolerate Nivolumab at most has not yet been clarified. However, the drug did not cause a serious side effect in the patients.
This drug, whose long-term safety has been established and which slows tumor growth, offers significant hope for extending survival in patients with advanced metastatic melanoma. Research is ongoing to obtain clearer results regarding the effect of this treatment. Nevertheless, such striking data indicate that this drug is a strong candidate for the standard treatment of patients with advanced skin cancer in the future.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.